NCT04856046Active, not recruiting
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Hepatocellular Carcinoma (ATHENA)
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
This study explores the potential values of a new blood test approach to detect measurable residual disease or early coming back of cancer (recurrence)/cancer growing, spreading, or getting worse (progression) in patients with liver cancer that can be removed by surgery (resectable). The development of novel cancer biomarkers for liver cancer may help in clinical decision making and lead to improvements in patient outcomes by facilitating prediction of the response to specific treatments, improved monitoring of patients on treatment, and better prognostication of patient outcomes, thus improving stratification for clinical trials.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 36 (actual)
- First submitted
- 14 Apr 2021
- Start date
- 6 Nov 2021
- Primary completion date
- 4 Dec 2029
- Lead sponsor
- Mayo Clinic
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT04856046
What you commit to
- Study type: Observational
- Participants enrolled: 36
- From 6 Nov 2021 to the primary completion date, 4 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient has known cancer outside of the liver 5 years prior to current blood collection (not including basal cell or squamous cell skin cancers)
- Patient has had a biopsy to the target organ and/or lesion within 3 days before blood collection
- Target pathology is a recurrence of previously treated HCC
- Patient has had prior resection or ablation for target lesion
- Patient has had prior or active chemotherapy or radiation for target lesion
Lab values
- Patient with significant anemia (hemoglobin \[Hb\] \< 7g/dL)
Age
- Patient is younger than 18 years of age
Other
- Females who are pregnant or attempt to become pregnant
- Patient has had an intervention to completely remove current target pathology
Who the study is looking for
- Patient has planned resection or ablation of suspected hepatocellular carcinoma
- Patient is classified as resectable T1/T2 hepatocellular carcinoma (HCC) (solitary tumors less than or equal to 2 cm OR solitary tumors without vascular invasion \> 2cm or solitary tumor with vascular invasion \> 2cm, or multiple tumors, none \> 5cm) OR BCLC stage A (Single lesion of ANY size or 3 nodules or less with each being 3cm or less)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.